BofA analyst Michael Ryskin lowered the firm’s price target on NeoGenomics (NEO) to $11 from $13 and keeps a Neutral rating on the shares. 1 results were “modestly positive, though unlikely to materially change the broader debate,” says the analyst, who updated the firm’s model for the results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target raised to $14 from $13 at TD Cowen
- NeoGenomics Buy Rating Reaffirmed as Growth and Profitability Improve; $15 Price Target Maintained
- Leerink upgrades NeoGenomics to Outperform, raises target to $25
- NeoGenomics upgraded to Buy from Hold at Benchmark
- NeoGenomics upgraded to Outperform from Market Perform at Leerink